About
Patient Care
Education
Research
Community
Topics
*Attention In-Person AttendeesProof of vaccination is required by the venue before you will be allowed to enter the building. You have two options:
Helpful Tip: Attain a digital COVID-19 vaccine record via state of California by clicking here, where you are able to take a screenshot of your QR code and keep for future proof.
Universal Masking/Face Coverings: All individuals will be required to wear a mask or face covering while indoors, regardless of vaccination status. The update is in line with the Centers for Disease Control and Prevention and the California Department of Public Health's recent recommendations on masking and face coverings.
PLEASE NOTE: You, you must complete a brief evaluation of our event in order to receive your CME certificate.
To begin, simply click on the link below, enter your personal information and begin the survey. At the end of the survey, you will be automatically emailed your CME certificate.
Please note that this evaluation must be completed and submitted online by December 2, 2022. This is the only way to confirm your attendance, which is required in order to receive CME credit.
COMPLETE CME CERTIFICATION EVALUATION HERE
Accreditation Statement: The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement: The University of California, Irvine School of Medicine designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit that is commensurate with the extent of their participation in the activity.
Baruch D. Kuppermann, MD, PhD and Sumit (Sam) Garg, MD
Moderators: Andrew Browne, MD, PhD and Mitul Mehta, MD
Moderator: Vivek Patel, MD
Moderators: Olivia Lee, MD and Matthew Wade, MD
Moderator: Austin Fox, MD
Moderator: Jeremiah Tao, MD
Moderator: Lilangi Ediriwickrema, MD
Moderator: Matthew Wade, MD
Moderator: Donny Suh, MD
Moderator: Sumit (Sam) Garg, MD
Course Director
Planning Committee
Visiting Faculty
Parking is free
AbbVie
AbbVie focuses on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women’s health, as well as through our Allergan Aesthetics portfolio. Supported by a grant from AbbVie
AcuFocus
AcuFocus, Inc., is a privately held ophthalmic medical device company that delivers breakthrough small-aperture intraocular products to address diverse unmet needs in eye care and help patients achieve their best personal vision. The IC-8® Apthera™ IOL (known as the IC-8 IOL internationally) is approved in the United States for the treatment of cataract patients. The Apthera IOL uses small aperture technology to filter out peripheral defocused light, allowing only focused light to reach the retina. This provides a true continuous depth of focus with patients with as much as 1.5 diopters (D) of corneal astigmatism. The lens also received CE mark in 2015 and is available in select markets across Europe as well as Australia, New Zealand, and Singapore. AcuFocus is based in Irvine, California. For more information about AcuFocus, visit www.acufocus.com.
Aerie Pharmaceuticals
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. They have a passion for finding new approaches for protecting or improving vision. United by VISIONaerie® Science, deep clinical insights, and a singular focus on addressing the unmet needs in ophthalmology, they see the possibilities ahead.
Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
Bausch + Lomb
By listening to feedback from customers, patients and consumers and using data-driven insights, we develop modernized vision care, consumer health care, surgical and pharmaceutical products to help millions of people worldwide see better to live better.
Coherus Biosciences
The first and only FDA-approved biosimilar interchangeable with Lucentis for all indications. For more information visit https://www.cimerli.com/
CorneaGen
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. Based in Seattle, the company is innovating the next generation of cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest products, delivery of the highest-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.
Dompe
Dompé is an Italian biopharmaceutical company with a 130 year legacy of medical innovation. Based in Milan with US headquarters in the San Francisco Bay Area, Dompé is committed to medical and scientific advancements that address unmet medical needs in the areas of ophthalmology, transplants, oncology, and diabetes. To learn more about Dompé, email USMedinfo@dompe.com
Genentech
Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases. To learn more, visit Website https://www.ophthalmologyvision.com/
Glaukos
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Their mission is to transform the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Horizon
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.
Johnson Johnson Vision
At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we've developed solutions for every stage of life-to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world's leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere. Click logo to watch video Learn more at www.jnjvisionpro.com/tecnissynergy
New World Medical
New World Medical was founded to benefit humanity. Our firm works to live up to this lofty goal by creating and manufacturing cutting-edge glaucoma surgical devices intended to alleviate the suffering of glaucoma patients globally. Dedicated surgical sales consultants provide support for New World Medical’s flagship products, which include the Ahmed® Glaucoma Valve, Ahmed ClearPath®, Kahook Dual Blade®, and KDB GLIDE® throughout the United States. Internationally, the company utilizes an exclusive distribution network to reach patients in need.
Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our robust product pipeline positions Ocular Therapeutix to become a leader in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current standard of care by developing sustained release alternatives.
SightSciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids.
Tarsus
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial. To learn more about Tarsus, please email info@tarsusrx.com.
Trefoil Therapeutics
Trefoil Therapeutics is a clinical stage company focused on the application of novel engineered FGF1 compounds in underserved ophthalmic disease areas. The lead compound, TTHX1114, is a regenerative compound that stimulates proliferation, migration, and protection of corneal endothelial and epithelial cells. The lead indication is Fuchs Dystrophy, a disease that is currently treated with corneal transplantation. Trefoil has completed two phase 2 studies with the intracameral injectable formulation for the treatment of Fuchs Dystrophy and will initiate a phase 1 study for the topical epithelial indication for the treatment of ulcerative corneal conditions in 2022.
Visus Therapeutics
Visus Therapeutics is a team of industry leaders with vast eye care experience and an unmatched track record in the development and commercialization of innovative eye care pharmaceuticals. The breadth and depth of our collective knowledge and experience allows us to set our sights on the future of eye health, united by the common goal of advancing drug discovery to benefit the patients we serve and dedicated to achieving a lifetime of clear vision.
Zeiss
With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, ZEISS Medical Technology supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.
Click registration button to see further details for
Need to reach out to us for questions regarding the event? Or, are you interested in becoming a sponsor or exhibitor? Please contact Dana Collinson for more information.
Dana Collinson | 949-824-7243 | dana.collinson@hs.uci.edu